1-2 of 2
Anastasios Karadimitris, FRCPath, PhD
Close
Sort by
Journal Articles

Clustering Analysis of Myeloma Clone Phenotype Is Informative for Disease Heterogeneity and Prognosis at Relapse

Syeda Maheen Ahsan, Elisabet Nadal-Melsio, MD, Mark E Robinson, PhD, Richard Syzdlo, PhD, Eva Yebra-Fernandez, MD, Holger W Auner, MD PhD, Maria Atta, MD, Marco Bua, MD, Farah O'Boyle, PhD, Kikkeri Naresh, Jane Apperley, MB ChB MD, Anastasios Karadimitris, FRCPath, PhD, Aristeidis Chaidos, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4492.
https://doi.org/10.1182/blood-2018-99-117460
Published: 2018
Journal Articles

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Michael Dickinson, MD, Manali Kamdar, MD, Brian J.P Huntly, Carlos Fernández De Larrea, MD PhD, Raul Cordoba, MD PhD, Maria-Victoria Mateos, MD PhD, Adrián Alegre, MD, Won-Seog Kim, MD PhD, Jin Seok Kim, MD PhD, Mark Dawson, MD PhD, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP, Faisal Basheer, MBBChir, MA, Paolo Gallipoli, PhD, Aristeidis Chaidos, MD PhD, Alejandro Martín, MD, Thierry Horner, PhD, James Winnberg, MS, Lijoy K Mathew, PhD, Jeffrey Botbyl, MS, Natalie Karpinich, PhD, Brandon E. Kremer, MD PhD, Arindam Dhar, MBBS,MDPhD, Anastasios Karadimitris, FRCPath, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1682.
https://doi.org/10.1182/blood-2018-99-117089
Published: 2018